Scientific Posters

Technical Data & Resources

12.06.2018

Diverse Inter- and Intra-patient Circulating Tumor Cells (CTCs) Phenotypic Heterogeneity Identified in Metastatic Breast Cancer (MBC) Patients

12.06.2018

Enabling detection of HER2 and AR protein expression and localization in circulating tumor cells (CTCs) of metastatic breast cancer (MBC) patients (pts)

11.13.2018

Measurement of SLFN11 protein in circulating tumor cells (CTCs) as a proposed liquid biopsy biomarker to predict response to DNA repair targeted therapies

11.16.2018

Diverse Inter- and Intra-patient Circulating Tumor Cells (CTCs) Phenotypic Heterogeneity Identified Across Multiple Metastatic Breast Cancer (mBCa) Cohorts

11.09.2018

Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy

10.22.2018

Evaluation of the clinical utility of the nuclear-localized AR-V7 biomarker in CTCs in the context of physician intuition measured through physician therapy choice propensity and patient risk

06.02.2018

Clonal Concordance and Genomic Heterogeneity in Single CTC Copy Number Alteration vs. Paired IMPACT Metastatic Tissue Sequencing from mCRPC Patient Samples

06.02.2018

Unique patterns of the Selection and Change in Circulating Tumor Cell (CTC) Phenotypes and Genotypes by Drug Class in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

06.02.2018

Analysis of circulating tumor cells (CTCs) in patients across multiple metastatic breast cancer (mBCa) cohorts identifies marked inter- and intra-patient heterogeneity in CTC size, shape, and overall morphology.

06.02.2018

Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.

04.18.2018

Simultaneous Characterization and Quantification of Immune Cell Subpopulations and PD-L1 Expressing CTCs in Peripheral Blood of Cancer Patients

04.17.2018

Low Pass Whole Genome Sequencing of Single Circulating Tumor Cells for Detection of Chromosomal Instability (CIN) and Non-Coding Indels Across Multiple Solid Tumors

04.15.2018

Prediction of Genomic Instability (GI) in Triple Negative Breast Cancer (TNBC) Patients Utilizing a CTC Phenotype Classifier

02.08.2018

Validation of Nuclear-Localized AR-V7 on Circulating Tumor Cells (CTC) as a Treatment-Selection Biomarker for Managing Metastatic Castration-Resistant Prostate Cancer (mCRPC)

02.08.2018

PSMA Heterogeneity Analysis in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Imaging Versus CTCs

10.27.2017

Comprehensive single cell analysis of tumor mutation burden (TMB), chromosomal instability (CIN), and microsatellite instability (MSI) on circulating tumor cells (CTCs). EORTC

10.26.2017

Quantification of rare PD-L1 and other immunology biomarker expressing leukocytes and CTCs in peripheral blood of cancer patients. EORTC

10.17.2017

Glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) prognosticates poor overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with androgen receptor signaling inhibitors (ARSi).

10.01.2017

Quantification of rare PD-L1 and other immunology biomarker expressing leukocytes and CTCs in peripheral blood of cancer patients. AACR

09.08.2017

Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes. ESMO

06.02.2017

Changes in CTC burden and phenotypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapeutics (Tx).

06.02.2017

Baseline circulating tumor cell (CTC) subtype predicts responses to enzalutamide but not abiraterone in metastatic castration-resistant prostate cancer (mCRPC) patients.

04.07.2017

Integrated single cell phenogenomic subtyping of CTCs identify inter-cellular tumor heterogeneity (het) and multiple resistance mechanisms in mCRPC patients (pts). ASCO GU

04.03.2017

Phenotypic, genomic, and clinical associations of circulating tumor cells (CTCs) lacking epithelial biomarkers in metastatic castration resistant prostate cancer (mCRPC). AACR 2017

09.15.2016

Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifier in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial.

06.03.2016

Programmed death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients with lung cancer. ASCO 2016

06.03.2016

AR-V7 status and CTC heterogeneity improve the prediction of drug sensitivity and patient outcomes for taxanes and qpproved AR targeted therapies. ASCO 2016

06.03.2016

CTC phenotype classifier identifies mCRPC patients with high genomic instability CTCs and predicts failure of Androgen Receptor signaling (AR Tx) and taxane systemic therapies. ASCO 2016

06.03.2016

Detection of glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) from patients with castration-resistant prostate cancer (CRPC). ASCO 2016

04.17.2016

Androgen receptor expression on circulating tumor cells (CTCs) in metastatic breast cancer. AACR 2016

04.16.2016

Validation of AR-V7 as a treatment-specific biomarker at decision points in management of castration-resistant prostate cancer. AACR 2016

01.08.2016

Single CTC characterization identifies phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients. ASCO GU 2016.

01.07.2016

Clinical validation of CTC subtype frequency to prognosis overall survival (OS) in metastatic castrate-resistant prostate cancer (mCRPC) patients. ASCO GU 2016

01.07.2016

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. ASCO GU 2016

01.04.2016

Characterization of programmed cell death-1 ligand (PD-L1) expression in circulating tumor cells (CTCs) of lung cancer. ACCR IASLC 2016

01.07.2016

The use of whole genome copy number variation (CNV) to measure genomic instability in mCRPC CTCs. ASCO GU 2016

11.05.2015

Single cell genomic profiling of circulating tumor cells (CTCs) from metastatic colorectal cancer (mCRC) identify tumor heterogeneity and rare somatic driver alterations. EORTC 2015

05.29.2015

Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC). ASCO 2015

05.29.2015

Circulating tumor cell (CTC) detection and 5T4 characterization in breast, ovarian, and lung cancer patients on active therapy. ASCO 2015

04.18.2015

Single cell analysis of AR N terminal, AR C terminal and the Arv7 splice variant in CTCs of metastatic castration resistant prostate cancer (mCRPC) patients. AACR 2015

04.18.2015

The expression of fetal oncogene 5T4 in CTCs obtained from NSCLC patients is discordant with the expression measured in the primary tumor. AACR 2015

02.26.2015

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients. ASCO GU 2015

11.18.2014

Characterization of molecular targets of therapy in non-small cell lung cancer (NSCLC) utilizing a liquid biopsy. EORTC 2014

11.18.2014

Characterization of PD-L1 expression in circulating tumor cells (CTCs) of non-small cell lung cancer (NSCLC) patients. EORTC 2014

09.26.2014

Characteristics of de novo resistance to androgen targeting therapeutics (AR Tx) through circulating tumor cells (CTCs) analysis in metastatic castration resistant prostate cancer (mCRPC) patients. ESMO 2014

01.30.2014

Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC). ASCO GU 2014

01.30.2014

Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC). ASCO GU 2014

01.06.2014

Characterization of ALK fusions in circulating tumor cells (CTCs) of NSCLC. AACR 2014